Khaled Moussawi, MD, PhD
Associate Professor
Neurology
School of Medicine

The Translational Neuropsychiatry Through Neuromodulaton (TN²) laboratory investigates the neurobiology of substance use disorders and uses neuromodulation tools such as Low-Intensity Focused Ultrasound (LIFU), Transcranial Magnetic Stimulation (TMS), and Deep Brain Stimulation (DBS) to treat drug and alcohol addiction and related neuropsychiatric disorders.

Show full bio (26 words) Hide full bio

The goal of the lab is to identify neural biomarkers of craving and drug-seeking behaviors and leverage those findings to develop individualized clinical treatments with neuromodulation.

Education & Training

Show all (5) Hide

  • Research Fellowship Substance use disorders National Institute on Drug Abuse (NIH/NIDA) 11/2020
  • Clinical Fellowship Neuropsychiatry Johns Hopkins Medicine 6/2017
  • Residency Neurology Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School 06/2016
  • Internship Internal Medicine Massachusetts General Hospital 06/2013
  • MD, PhD Medicine, Neuroscience Medical University of South Carolina 05/2012

Websites

Show all (1) Hide

Grants and Projects

Show all (3) Hide

Publications (39)

Top publication keywords:
Ventral StriatumCocaine-Related DisordersAcetylcysteineReceptors, Metabotropic Glutamatealpha7 Nicotinic Acetylcholine ReceptorDeep Brain StimulationDopaminergic NeuronsG Protein-Coupled Inwardly-Rectifying Potassium ChannelsReceptors, Dopamine D1CocaineFentanylDrug-Seeking BehaviorReceptors, GlycineGlobus PallidusMesencephalon

Show all (34 more) Hide